{"nctId":"NCT00522275","briefTitle":"Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures","startDateStruct":{"date":"2004-10"},"conditions":["Partial Epilepsies"],"count":308,"armGroups":[{"label":"Lacosamide","type":"EXPERIMENTAL","interventionNames":["Drug: lacosamide"]}],"interventions":[{"name":"lacosamide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completion of parent clinical trial for treatment of partial seizures\n\nExclusion Criteria:\n\n* Receiving any study drug or experimental device other than lacosamide\n* Meets withdrawal criteria for parent trial or experiencing ongoing serious adverse event","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (Maximum 6 Years)","description":"Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"288","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Prematurely Discontinuing Due to a Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (Maximum 6 Years)","description":"Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Reporting at Least 1 Serious Adverse Event (SAE) During the Treatment Period (Maximum 6 Years)","description":"Serious adverse events are any untoward serious medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Percentage Change From Baseline in 28-day Seizure Frequency During the Treatment Period (Maximum 6 Years)","description":"Negative changes from Baseline indicate an improvement (i.e., a reduction) in 28-day seizure frequency.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of at Least 50 % Responders During the Treatment Period (Maximum 6 Years)","description":"At least 50 percent response is based on the percentage reduction in 28-day seizure frequency during the Treatment Period of the open-label extension relative to the Baseline Phase of the prior study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":71,"n":308},"commonTop":["Dizziness","Headache","Contusion","Nausea","Nasopharyngitis"]}}}